Treatment as Prevention¨

The FDA has approved Descovy, a fixed-dose combination tablet containing emtricitabine and tenofovir alafenamide, for the treatment of HIV, according to the drug’s manufacturer. Descovy (emtricitabine/tenofovir alafenamide [F/TAF]; Gilead Sciences) is administered as a single oral tablet taken daily in combination with other antiretroviral agents. The formulation includes 200 mg emtricitabine and 25 mg tenofovir […]

Segment from 1:40:13 – 1:49:33

TORONTO – Canadian researchers have determined the peak of the hepatitis C epidemic in North America occurred about 15 years earlier than previously believed, suggesting it wasn’t youthful indiscretions that put baby boomers at a high risk for the disease. And that means, say researchers, that all those who belong to the post-Second World War

A novel investigation into the North American spread of hepatitis C virus permits blame shifting, which the authors Jeffrey Joy and colleagues hope will increase the number of baby boomers who undergo testing. The medical community can now take its share of the responsibility for hepatitis C virus infection in its conversations with the 1945-65

As a youth growing up in Chicago, Phill Wilson had a Cuban fetish. The Spanish literature major romanticized the island nation, which was off-limits to U.S. travelers since the Cuban Missile Crisis of 1963. A half-century later, Wilson – now the out president of the Los Angeles-based Black AIDS Institute -would find himself en route

Imagine seeing a patient every eight weeks for a few quick injections into the buttocks that could prevent HIV between appointments. That’s the promise of the ÉCLAIR trial of the investigational integrase strand transfer inhibitor cabotegravir, which had its phase-2 results unveiled at CROI 2016 in February. ÉCLAIR was one of two trials of long-acting

This blog was originally written for BMJ Clinical Evidence and posted on blogs.bmj.com/ce/ Last week saw a landmark shift in the pre-exposure prophylaxis (PrEP) for HIV debate in England. After 18 months of work with key stakeholders-including clinicians, commissioners, and community advocates-NHS England announced that it was no longer able to fund a significant PrEP